.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,409,616

« Back to Dashboard

Claims for Patent: 8,409,616

Title:Extended release opioid abuse deterrent compositions and methods of making same
Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
Inventor(s): Kumar; Vijai (Morris Plains, NJ), Dixon; David (Woodside, NY), Tewari; Divya (Suffern, NY), Wadgaonkar; Dilip B. (Suffern, NY)
Assignee: Acura Pharmaceuticals, Inc. (Palatine, IL)
Application Number:13/327,252
Patent Claims: 1. A therapeutic pharmaceutical composition comprising: a mixture including (a) a water soluble drug susceptible to abuse at about 0.5 to about 25 percent by weight; (b) gel-forming polymer at about 3 to about 40 percent by weight; (c) a disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (d) sorbitan monoester at about 1 to 10 percent by weight.

2. The therapeutic pharmaceutical composition of claim 1, wherein the gel-forming polymer is polyethylene oxide.

3. The therapeutic pharmaceutical composition of claim 2, wherein the polyethylene oxide has an average molecular weight ranging from 300,000 to about 5,000,000.

4. The therapeutic pharmaceutical composition of claim 1, wherein the sorbitan monoester is present in an amount of about 1 to about 3 percent by weight.

5. The therapeutic pharmaceutical composition of claim 1, wherein the disintegrant comprises croscarmellose sodium.

6. The therapeutic pharmaceutical composition of claim 1, further comprising microcrystalline cellulose.

7. The therapeutic pharmaceutical composition of claim 1, further comprising polyethylene glycol.

8. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in unit dose form.

9. The therapeutic pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

10. A therapeutic pharmaceutical composition comprising: a mixture including (a) a water soluble drug susceptible to abuse; (b) a gel-forming polymer in an amount of about 3 to about 40 wt %; (c) a disintegrant; and (d) a surfactant; wherein the disintegrant is present in an amount sufficient to cause the pharmaceutical composition to exhibit an immediate release profile.

11. The therapeutic pharmaceutical composition of claim 10, wherein the pharmaceutical composition is in unit dose form.

12. The therapeutic pharmaceutical composition of claim 10, wherein the pharmaceutical composition is in suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.

13. The therapeutic pharmaceutical composition of claim 10, wherein the water soluble drug susceptible to abuse is present in an amount of 0.5 to about 25 wt % of the composition.

14. The therapeutic pharmaceutical composition of claim 10, wherein the disintegrant is present in an amount of about 2 to about 25 wt % of the composition.

15. The therapeutic pharmaceutical composition of claim 10, wherein the surfactant is present in an amount of about 1 to about 10 wt % of the composition.

16. The therapeutic pharmaceutical composition of claim 10, wherein the gel-forming polymer is present in an amount of about 3 to about 40 wt % of the composition.

17. The therapeutic pharmaceutical composition of claim 10, wherein the disintegrant is selected from the group consisting of sodium starch glycolate, crospovidone, and croscarmellose sodium.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc